DP

Dale Pfost

Biotechnology Entrepeneur, Executive and Board Member

United States

Overview 

Dale Pfost is a highly accomplished biotechnology entrepreneur and executive, currently serving as Co-Chairman of the Board at AxoSim and a Board Member at Ancilia Biosciences. Notable highlights of his career include serving as CEO and Chairman of the Board at Chemomab Therapeutics and Lodo Therapeutics Corporation, showcasing his strong leadership and strategic acumen in the biotechnology industry.

Work Experience 

  • Co-Chairman of the Board

    2024 - Current

  • Board Member

    2018

AxoSim is an operator of a biomimetic neuroscience discovery platform used to develop a 3D cell-based platform.

Raised $14,189,233.00 from New Orleans BioFund.

  • Board Member

    2021

  • board member

    2009 - 2024

    http://www.jmbcompanies.com

  • Chief Executive Officer and Chairman of the Board

    2021 - 2023

    Chemomab is a clinical stage public company developing innovative treatments for patients with diseases stemming from inflammation and fibrosis

  • Business Owner

    2010 - 2021

  • Chief Executive Officer and Chairman of the Board

    2019 - 2021

    About Lodo Therapeutics Lodo discovers and develops novel therapeutics addressing undruggable targets by applying its proprietary platform to tap the vast collections of undiscovered molecules encoded in environmental microbial DNA. These evolutionarily optimized leads include structurally diverse molecules with drug-like properties that have been largely inaccessible until now. The Lodo platform leverages breakthroughs in next-generation sequencing, artificial intelligence/machine learning and synthetic biology to increase speed and efficiency by orders of magnitude. Following successful initial collaborations with two global partners, Lodo is developing an internal pipeline of oncology drugs and expanding its partnering activities in a range of indications. Lodo is an Accelerator Life Science Partners-backed entity headquartered in New York City. For more information, visit lodotherapeutics.com

  • Acting CEO

    2016 - 2020

    MicroBiome Therapeutics (MBT) is an evidenced-based life-sciences company focusing on the use of natural food extracts as next-generation GI microbiome modulators for health. MBT has recently launched BiomeBliss, a clinically-tested prebiotic drink, which acts as a diet aid by naturally helping the activity of the GI microbiome. corporate: mbiome.com product: biomebliss.com

  • General Partner

    2011 - 2019

    Advent Life Sciences LLP is one of Europe’s leading venture teams investing in life sciences businesses. We are a deliberately small, and highly focused team of senior individuals, with long-standing track records of entrepreneurial and investment success across Europe and the USA. We invest predominantly in early and mid-stage life sciences companies in the UK, Europe and the US. We seek to back truly innovative companies that have a first-in-class or best-in-class approach, and are looking for a well-connected partner on the road to success. Our investments cover a range of sectors within life sciences, including new drug discovery, enabling technologies, med tech and diagnostics.

  • CEO -- remained as board member to Q1 2020

    2009 - 2011

    MicroBiome Therapeutics (previously known as NuMe Health) is a clinical stage biotechnology company focusing on using insights into the human microbiome for managing prediabetes with microbiome modulators including novel pharmaceuticals and medical foods

  • Venture Partner

    2010 - 2010

    Venture Capital in Life Sciences

Education 

Articles About Dale

Relevant Websites